All 'Bye' Itself: Alcon Spins Out From Novartis In $25Bn Stock Listing

09 Apr 2019

• By Catherine Longworth

Alcon is going it alone following a spin-out from Swiss pharma giant Novartis. The eye-care device business officially listed on the SIX Stock Exchange on April 9 with a total market capitalization of around $28bn, making it Switzerland's biggest stock deal in a decade.

Close-up of blue eye. High Technologies in the futuristic. : cataract

Novartis has completed the spin-off of eye-care devices business Alcon in Switzerland's biggest stock deal in a decade. Alcon officially listed on the SIX Swiss Stock Exchange April 9, with a market capitalization of over $25bn.

The Geneva-based company is the largest ophthalmic device maker in the world, with complementary businesses in surgical and vision care,...